Correlation Between Opus Genetics, and Zenas BioPharma,

Can any of the company-specific risk be diversified away by investing in both Opus Genetics, and Zenas BioPharma, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Opus Genetics, and Zenas BioPharma, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Opus Genetics, and Zenas BioPharma, Common, you can compare the effects of market volatilities on Opus Genetics, and Zenas BioPharma, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Opus Genetics, with a short position of Zenas BioPharma,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Opus Genetics, and Zenas BioPharma,.

Diversification Opportunities for Opus Genetics, and Zenas BioPharma,

0.55

Correlation Coefficient

Opus Genetics,  Zenas BioPharma,

Very weak diversification

The 3 months correlation between Opus and Zenas is 0.55. Overlapping area represents the amount of risk that can be diversified away by holding Opus Genetics, and Zenas BioPharma, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Zenas BioPharma, Common and Opus Genetics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Opus Genetics, are associated (or correlated) with Zenas BioPharma,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Zenas BioPharma, Common has no effect on the direction of Opus Genetics, i.e., Opus Genetics, and Zenas BioPharma, go up and down completely randomly.

Pair Corralation between Opus Genetics, and Zenas BioPharma,

Considering the 90-day investment horizon Opus Genetics, is expected to generate 1.18 times more return on investment than Zenas BioPharma,. However, Opus Genetics, is 1.18 times more volatile than Zenas BioPharma, Common. It trades about 0.03 of its potential returns per unit of risk. Zenas BioPharma, Common is currently generating about -0.03 per unit of risk. If you would invest  98.00  in Opus Genetics, on September 22, 2024 and sell it today you would earn a total of  0.00  from holding Opus Genetics, or generate 0.0% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Opus Genetics,  vs.  Zenas BioPharma, Common

Opus Genetics,

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Opus Genetics, has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Zenas BioPharma, Common

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Zenas BioPharma, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Etf's forward indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the ETF investors.

Pair Trading with Opus Genetics, and Zenas BioPharma,

The main advantage of trading using opposite Opus Genetics, and Zenas BioPharma, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Opus Genetics, position performs unexpectedly, Zenas BioPharma, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zenas BioPharma, will offset losses from the drop in Zenas BioPharma,'s long position.

The idea behind Opus Genetics, and Zenas BioPharma, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.